(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

BNTX: Cancer Vaccines, Immunotherapies, Infectious Disease Treatments

BioNTech SE is a German-based biotechnology company that specializes in developing and commercializing immunotherapies, primarily focusing on mRNA-based treatments for cancer and infectious diseases. The company has gained recognition for its innovative approach to harnessing the immune system to fight various diseases.

BioNTech has a robust pipeline of product candidates, with multiple assets in clinical trials across different types of cancer. Their FixVac platform includes several promising candidates, such as BNT111, which is currently in Phase II clinical trials for advanced melanoma. Additionally, BNT112 is being tested in Phase I/IIa trials for prostate cancer, while BNT113 is in Phase II trials for HPV 16+ head and neck cancers. The company is also exploring BNT114 for triple-negative breast cancer and BNT115 for ovarian cancer, both in Phase I clinical trials.

Beyond these, BioNTech is investigating BNT116 for non-small cell lung cancer and BNT122 for both first-line melanoma and multiple solid tumors. The pipeline further extends to BNT131, BNT141, BNT142, BNT151, BNT152, BNT153, BNT211, and BNT221, all of which are being evaluated for their potential in treating various solid tumors. BNT311 is in Phase II trials for metastatic non-small cell lung cancer and is also being tested in Phase I/II trials for multiple solid tumors. BNT312 is in Phase II trials for multiple solid tumors, and ONC-392 is in Phase III trials for ovarian cancer, with additional Phase I/II trials for multiple solid tumors.

The company is also developing several other candidates, including BNT321, an IgG1 monoclonal antibody in Phase I trials for pancreatic cancer, and BNT411, a small molecule immunomodulator in Phase I trials for solid tumors. BNT322 is in Phase I/Ib trials for multiple solid tumors. Additionally, BioNTech is working on prophylactic vaccines for infectious diseases such as shingles, malaria, tuberculosis, and HSV-2.

BioNTech has established strategic collaborations with key industry players, including Genentech, Sanofi, Genmab, Pfizer, Shanghai Fosun Pharmaceutical, and Ryvu Therapeutics. These partnerships highlight the companys commitment to advancing its pipeline and expanding its reach in the global market.

From a financial perspective, BioNTech has a market capitalization of $28.754 billion USD, with a price-to-book ratio of 1.42 and a price-to-sales ratio of 9.46. While the company currently has a P/E ratio of

Additional Sources for BNTX Stock

BNTX Stock Overview

Market Cap in USD 22,785m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2019-10-10

BNTX Stock Ratings

Growth 5y 27.3%
Fundamental -54.5%
Dividend 1.0%
Rel. Strength 16.3
Analysts 4.33/5
Fair Price Momentum 82.16 USD
Fair Price DCF -

BNTX Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 1.7%

BNTX Growth Ratios

Growth Correlation 3m -72.1%
Growth Correlation 12m 62.9%
Growth Correlation 5y -7.7%
CAGR 5y 11.64%
CAGR/Max DD 5y 0.14
Sharpe Ratio 12m -1.33
Alpha -7.19
Beta 0.308
Volatility 50.25%
Current Volume 1140.7k
Average Volume 20d 866.4k
What is the price of BNTX stocks?
As of April 02, 2025, the stock is trading at USD 90.29 with a total of 1,140,704 shares traded.
Over the past week, the price has changed by -6.97%, over one month by -19.07%, over three months by -21.69% and over the past year by -3.04%.
Is BioNTech SE a good stock to buy?
No, based on ValueRay Fundamental Analyses, BioNTech SE (NASDAQ:BNTX) is currently (April 2025) a stock to sell. It has a ValueRay Fundamental Rating of -54.45 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNTX as of April 2025 is 82.16. This means that BNTX is currently overvalued and has a potential downside of -9%.
Is BNTX a buy, sell or hold?
BioNTech SE has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy BNTX.
  • Strong Buy: 12
  • Buy: 4
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BNTX stock price target?
According to ValueRays Forecast Model, BNTX BioNTech SE will be worth about 89.3 in April 2026. The stock is currently trading at 90.29. This means that the stock has a potential downside of -1.1%.
Issuer Forecast Upside
Wallstreet Target Price 138.2 53%
Analysts Target Price 136.6 51.3%
ValueRay Target Price 89.3 -1.1%